Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement - Array BioPharma (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended	9 Months Ended
		Jul. 30, 2019	Sep. 29, 2019	Sep. 29, 2019	Sep. 30, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Acquisition of business, net of cash acquired	[1]			$ 10,861	$ 0
Goodwill	[2]		$ 58,665	58,665		$ 53,411
Array [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 48
Payments for acquisition, cash portion		$ 11,200
Acquisition of business, net of cash acquired		10,900
Identifiable intangible assets		7,200
Goodwill		5,400
Deferred tax liabilities		1,300
Assumed long-term debt		451
Array [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 1,800
Acquired intangible assets, average useful life		16 years
IPR&D [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 4,000
Licensing Agreements [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		1,400
Technology in development [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		1,100
Developed technology [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 340
Useful life of acquired intangibles		10 years
Restructuring charges and acquisition-related costs [Member] | Array [Member]
Business Acquisition [Line Items]
Post-closing compensation expense for payments to Array employees for fair value of previously unvested stock options			$ 157	$ 157

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.